Transcriptome-wide analysis of compression-induced microRNA expression alteration in breast cancer for mining therapeutic targets

Oncotarget

Volumn 7, Issue 19, 2016, Pages 27468-27478

  Kim, Baek Gil ^a   Kang, Suki ^a   Han, Hyun Ho ^a   Lee, Joo Hyun ^a   Kim, Ji Eun ^a   Lee, Sung Hwan ^a   Cho, Nam Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Breast cancer; Compression; Incurable cancer therapy; microRNA; Transcriptome

Indexed keywords

MICRORNA; MICRORNA 1288; MICRORNA 1471; MICRORNA 3127; MICRORNA 3654; MICRORNA 4446; MICRORNA 4486; MICRORNA 4538; MICRORNA 4665; MICRORNA 4733; MICRORNA 4769; MICRORNA 513B; MICRORNA 577; MICRORNA 617; MICRORNA 628; MICRORNA 644A; MICRORNA 664B; MICRORNA 671; MICRORNA 99B; TRANSCRIPTOME; UNCLASSIFIED DRUG; MESSENGER RNA;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CELL ADHESION; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL SPECIFICITY; COMPRESSION; COMPRESSION INDUCED MICRORNA EXPRESSION ALTERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC PARAMETERS; HUMAN; HUMAN TISSUE; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MECHANICAL COMPRESSION; MICROARRAY ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); TRANSCRIPTOME WIDE ANALYSIS; TRANSCRIPTOMICS; TUMOR GROWTH; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; MCF-7 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MCF-7 CELLS; MICRORNAS; MOLECULAR TARGETED THERAPY; RNA, MESSENGER; TRANSCRIPTOME; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84968719065     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8322     Document Type: Article

References (49)

1. Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins JN, Acerbi I, Ou G, Wijekoon AC, Levental KR, Gilbert PM, Hwang ES, Chen YY and Weaver VM. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med. 2014; 20:360-367.
2. Shieh AC. Biomechanical Forces Shape the Tumor Microenvironment. Ann Biomed Eng. 2011; 39:1379-1389.
3. Stylianopoulos T, Martin JD, Snuderl M, Mpekris F, Jain SR and Jain RK. Coevolution of Solid Stress and Interstitial Fluid Pressure in Tumors During Progression: Implications for Vascular Collapse. Cancer Res. 2013; 73:3833-3841.
4. Chen Y, Mohammed A, Oubaidin M, Evans CA, Zhou X, Luan X, Diekwisch TG and Atsawasuwan P. Cyclic stretch and compression forces alter microRNA-29 expression of human periodontal ligament cells. Gene. 2015; 566:13-17.
5. Dunn W, DuRaine G and Reddi AH. Profiling MicroRNA Expression in Bovine Articular Cartilage and Implications for Mechanotransduction. Arthritis Rheum. 2009; 60:2333-2339.
6. Jin L, Zhao J, Jing WS, Yan SJ, Wang X, Xiao C and Ma BA. Role of miR-146a in human chondrocyte apoptosis in response to mechanical pressure injury in vitro. Int J Mol Med. 2014; 34:451-463.
7. Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins JN, Acerbi I, Ou GQ, Wijekoon AC, Levental KR, Gilbert PM, Hwang ES, Chen YY and Weaver VM. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med. 2014; 20:360-+.
8. Wells RG. Tissue mechanics and fibrosis. Bba-Mol Basis Dis. 2013; 1832:884-890.
9. Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan M, Jeon YJ, Li B, Vicentini C, Peng Y, Lee TJ, Luo Z, Liu L, Xu D, Tili E, Jin V, et al. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2015.
10. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133:647-658.
11. Chen PS, Su JL, Cha ST, Tarn WY, Wang MY, Hsu HC, Lin MT, Chu CY, Hua KT, Chen CN, Kuo TC, Chang KJ, Hsiao M, Chang YW, Chen JS, Yang PC, et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. The Journal of clinical investigation. 2011; 121:3442-3455.
12. Kasinski AL and Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature reviews Cancer. 2011; 11:849-864.
13. Hanahan D and Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011; 144:646-674.
14. Paszek MJ and Weaver VM. The tension mounts: mechanics meets morphogenesis and malignancy. Journal of mammary gland biology and neoplasia. 2004; 9:325-342.
15. Siolas D and Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013; 73:5315-5319.
16. Garman KS, Nevins JR and Potti A. Genomic strategies for personalized cancer therapy. Human molecular genetics. 2007; 16 Spec No. 2:R226-232.
17. Hayden EC. Personalized cancer therapy gets closer. Nature. 2009; 458:131-132.
18. Dexter DL and Leith JT. Tumor heterogeneity and drug resistance. Journal of clinical oncology. 1986; 4:244-257.
19. Turner NC and Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. The Lancet Oncology. 2012; 13:e178-185.
20. Easwaran H, Tsai HC and Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Molecular cell. 2014; 54:716-727.
21. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer cell. 2006; 10:515-527.
22. Holliday DL and Speirs V. Choosing the right cell line for breast cancer research. Breast cancer research: BCR. 2011; 13:215.
23. Tse JM, Cheng G, Tyrrell JA, Wilcox-Adelman SA, Boucher Y, Jain RK and Munn LL. Mechanical compression drives cancer cells toward invasive phenotype. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:911-916.
24. Guan YJ, Yang X, Wei L and Chen Q. MiR-365: a mechanosensitive microRNA stimulates chondrocyte differentiation through targeting histone deacetylase 4. FASEB. 2011; 25:4457-4466.
25. Huang Y, Crawford M, Higuita-Castro N, Nana-Sinkam P and Ghadiali SN. miR-146a regulates mechanotransduction and pressure-induced inflammation in small airway epithelium. FASEB. 2012; 26:3351-3364.
26. Chavez KJ, Garimella SV and Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast disease. 2010; 32:35-48.
27. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute. 1996; 88:1529-1542.
28. Klijn JG, Setyono-Han B and Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000; 65:825-830.
29. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of clinical oncology. 1996; 14:737-744.
30. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
31. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
32. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008; 27:2128-2136.
33. Lee YS and Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes & development. 2007; 21:1025-1030.
34. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM and Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:E1695-1704.
35. Hu G, Chen D, Li X, Yang K, Wang H and Wu W. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer biology & therapy. 2010; 10:190-197.
36. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS and Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS one. 2009; 4:e6816.
37. Jaalouk DE and Lammerding J. Mechanotransduction gone awry. Nature reviews Molecular cell biology. 2009; 10:63-73.
38. Aguirre JI, Plotkin LI, Gortazar AR, Millan MM, O'Brien CA, Manolagas SC and Bellido T. A novel ligandindependent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. The Journal of biological chemistry. 2007; 282:25501-25508.
39. Yatabe J, Sanada H, Yatabe MS, Hashimoto S, Yoneda M, Felder RA, Jose PA and Watanabe T. Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II. American journal of physiology Renal physiology. 2009; 296:F1052-1060.
40. Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya Y, Imaizumi S, Fujino M, Ito K, Zou Y, Fukuhara S, Kunimoto S, Fukuzaki K, Sato T, Ge J, Mochizuki N, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO reports. 2008; 9:179-186.
41. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS and Niederhuber J. Silencing of miR-148a in cancerassociated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. 2013; 32:3246-3253.
42. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L, Colarossi C, Francescangeli F, Biffoni M, Collura D, Giacobbe A, D'Urso L, Falchi M, Venneri MA, Muto G, De Maria R, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011; 30:4231-4242.
43. Bauer M, Su G, Casper C, He R, Rehrauer W and Friedl A. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene. 2010; 29:1732-1740.
44. Drake LE and Macleod KF. Tumour suppressor gene function in carcinoma-associated fibroblasts: from tumour cells via EMT and back again? The Journal of pathology. 2014; 232:283-288.
45. Quail DF and Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19:1423-1437.
46. Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS and Cho NH. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci. 2010; 123:3507-3514.
47. De Ceuninck F, Lesur C, Pastoureau P, Caliez A and Sabatini M. Culture of chondrocytes in alginate beads. Methods in molecular medicine. 2004; 100:15-22.
48. Hua Q, Yang C, Oshima T, Mori H and Shimizu K. Analysis of gene expression in Escherichia coli in response to changes of growth-limiting nutrient in chemostat cultures. Applied and environmental microbiology. 2004; 70:2354-2366.
49. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ and Marra MA. Circos: an information aesthetic for comparative genomics. Genome research. 2009; 19:1639-1645.